Nanotech investment will have payoff
A recent report by Credit Suisse analysts found that investing in medical nanotechnology could have a real payoff in the coming years. Oncology and CNS diseases in particular will be a target for nanotech drug developers, which include, Flamel Technologies, Sandvik and Orthovita. Intellectual property and the attitudes of agencies faced with regulating nanotech trials will prove to be challenges, however. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
